PF 07295324
Alternative Names: PF-07295324Latest Information Update: 17 Aug 2023
At a glance
- Originator Pfizer
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Janus kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis
Most Recent Events
- 02 May 2023 Discontinued - Phase-I for Atopic dermatitis (In volunteers) in USA (Topical) (Pfizer pipeline, August 2023)
- 12 Aug 2022 Pfizer completes a phase I trial in Atopic dermatitis (In volunteers) in USA (Topical) (NCT05206604)
- 09 Feb 2022 Phase-I clinical trials in Atopic dermatitis in USA (Topical) (Pfizer pipeline, May 2022) (NCT05206604)